Epocrates mobile app adds disease areas

Share this article:
Epocrates mobile app adds disease areas
Epocrates mobile app adds disease areas

Epocrates expanded its mobile resource centers, adding disease-specific areas underwritten by pharma advertisers.

The resource centers, targeted to clinicians, provide medical commentaries and updates on the diagnosis and treatment of prevalent conditions, including atrial fibrillation, Alzheimer's disease, diabetes, epilepsy, infection management, pain management and venous thromboembolism, according to a company statement.

The disease-specific areas also deliver “unobtrusive branded messages” to docs, according to an Epocrates spokesperson. The application is available as a free download for Palm and Windows mobile devices, as well as iPhones. One in three physicians in the US uses Epocrates mobile or web-based software, according to the company's website.

Emerging Solutions in Pain, a division of MediCom Worldwide, launched an iPhone app for docs working in pain management and addiction earlier in the week. That application is also free, and provides journal summaries, clinical trial results and an ESP radio function, but is only available on the iPhone.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...